* Cocrystal Pharma Inc COCP.OQ COCP.O is expected
to show no
change in quarterly revenue when it reports results on May 13
(estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Cocrystal Pharma Inc is
for a
loss of 54 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cocrystal
Pharma
Inc is $10.00, above its last closing price of $1.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.58 -0.60 -0.44 Beat 26.3
Sep. 30 2023 -0.50 -0.53 -0.41 Beat 22.6
Jun. 30 2023 -0.53 -0.58 -0.41 Beat 29.3
Mar. 31 2023 -0.59 -0.67 -0.64 Beat 5.2
Dec. -0.72 -0.73 -0.55 Beat 24.3
31 2022
Sep. 30 2022 -0.48 -0.48 -0.70 Missed -45.8
Jun. 30 2022 -0.54 -0.52 -3.00 Missed -477
Mar. 31 2022 -0.36 -0.42 -0.48 Missed -14.3
This summary was machine generated May 10 at 15:47 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)